[¾÷°è¿ì´ë/¼º°ú±ÞÁ¦°ø ]
T cell engager(ÀÌÁßÇ×üTCE) ¿¬±¸
* KPI¿¡ µû¸¥ ¼º°ú±ÞÁö±Þ, ¾÷¿ì´ë ´ë¿ì
¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç
| ¸ðÁýºÎ¹® | ´ã´ç¾÷¹« | ÀÚ°Ý¿ä°Ç | Àοø |
|---|---|---|---|
¾÷°è¿ì´ë / T cell engager(ÀÌÁßÇ×ü/TCE) |
[´ã´ç¾÷¹«] - T cell engager(TCE) In vitro assay ¼öÇà ¹× Ç÷§Æû ±¸Ãà: cancer cell culture, immune cell(PBMC/T cell) handling, co-culture Á¶°Ç ÃÖÀûÈ |
[ÀÚ°Ý¿ä°Ç] °æ·Â: ½ÅÀÔ/°æ·Â 4³â¡è(¼®»çÀÌ»ó) [¿ì´ë»çÇ×] - T cell engager(TCE) ¼öÇà °æÇè(¼³°è¡æin vitro POC¡æ¸®µå ÃÖÀûÈ Áß 1°³ ÀÌ»ó ´Ü°è¿¡¼ ÁÖµµÀû ¿ªÇÒ) - ´Ù¾çÇÑ TCE Æ÷¸Ë/±âÀü ºñ±³(affinity tuning, CD3 arm ¼³°è/¾ÈÀü¼º °í·Á µî) °æÇè - MOA °íµµÈ °æÇè(¿¹: phospho-flow, activation signaling, ¸é¿ª½Ã³À½º/engagement Á¤·®, target density-dependent activity µî) - Cytokine release/over-activation risk °üÁ¡ÀÇ in vitro ¾ÈÀü¼º Æò°¡ °æÇè - ³í¹®/ƯÇã µî ¿¬±¸ ¼º°ú º¸À¯ - TCE ¹× ¸é¿ªÇ×¾ÏÇ×ü FDA ¹× MFDS IND packaging °æ·Â - ¹Ú»ç±Þ ¿ì´ë |
0 ¸í |
±Ù¹«Á¶°Ç
ÀüÇü´Ü°è ¹× Á¦Ãâ¼·ù
Á¢¼ö¹æ¹ý
ä¿ë½Ã
±âŸ À¯ÀÇ»çÇ×
00